Skip to main content

Muscle Relaxants Fail, Neuromodulators May Help in RA Pain

February 9, 2012 — Even small changes in pain intensity may greatly affect quality of life for patients with rheumatoid arthritis (RA). Muscle relaxants and neuromodulators have been tried as agents for improving RA pain control, but 2 Cochrane systematic reviews by Bethan Richards, MBBS, MMed, M Sports Med, and colleagues, published online January 18, conclude that only topical capsaicin merits consideration as add-on therapy.
Dr. Richards, who is medical superintendent and staff specialist in rheumatology at the Royal Prince Alfred Hospital Institute of Rheumatology and Orthopedics, Camperdown, Australia, told Medscape Medical News, "It should be stressed that the current evidence available is weak, based on small numbers of patients, and was carried out in a prebiologic era. We found weak evidence (6 trials, 126 participants) in the muscle relaxant paper that neither the benzodiazepine agents (diazepam and triazolam) nor the non-benzodiazepine agent (zopiclone) reduce pain when taken for 1 to 14 days. However, even this short use was associated for both agents with drowsiness and dizziness.
"In the neuromodulator paper," Dr. Richards continued, "we found that there was weak evidence (4 trials, 141 participants) that using oral nefopam, topical capsaicin, and oromucosal cannabis for 1 to 7 days can reduce pain in patients with rheumatoid arthritis better than placebo. Each of these agents was associated with a significant side effect profile, which for oral nefopam and cannabis seemed to outweigh the benefits. These agents are also difficult to access. Nefopam is not widely available, and cannabis is illegal in many parts of the world. However, given the relatively mild nature of the adverse events (local burning), capsaicin could be considered as an add-on therapy for patients with persistent local pain and an inadequate response or intolerance to other treatments."
The reviewers analyzed randomized controlled trials that compared a muscle relaxant with another therapy (active, including nonpharmacological therapies, or placebo) in adult patients with RA and that reported at least 1 clinically relevant outcome. This included benzodiazepines (diazepam, triazolam) and zopiclone.
They also analyzed randomized controlled trials that compared any neuromodulator with another therapy (active or placebo, including nonpharmacological therapies) in adult patients with RA who had at least 1 clinically relevant outcome measure. This included anticonvulsants, ketamine, bupropion, methylphenidate, nefopam, capsaicin, and the cannabinoids.
"From a clinician's point of view, the evidence presented in the analysis is very weak and not reflective of current-day patients with rheumatoid arthritis. Hence we are currently forced to extrapolate from the better-quality data available on these agents in other patient populations (knowing patients with RA may not respond the same way) and use our own clinical judgment. This is obviously not ideal, but the best we have until better quality trials in patients with RA become available," Dr. Richards said.
The researchers were surprised at the lack of high-quality trials in patients with RA, in whom pain control is a high priority. "The trials that were available were small and of low quality. In particular, there were no studies on neuromodulators such as pregabalin and gabapentin, which are often used in clinical practice," Dr. Richards said.
The researchers also warn that the populations included in this review are not reflective of current-day patients with RA. They write, "More than half the included trial participants were inpatients who were hospitalised with poorly controlled disease. Many were only receiving [nonsteroidal anti-inflammatory drugs], or occasionally low dose corticosteroids or [disease-modifying antirheumatic drugs], reflective of practice at the time. The patients selected for inclusion were predominantly women and had various degrees of RA disease severity. It was unclear what other analgesics they were taking at the time of the studies and whether the patients had any co-morbidities. It also remains unclear as to what type of pain these agents were being used for."
The authors have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Sitting at Work Raises All-Cause and CV Mortality Risk

May 21, 2012 (Lyon, France) — Sitting at work raises the risk of dying from cardiovascular (CV) and metabolic diseases, as well as the risk of dying from all causes, regardless of any exercise in which the individual may engage. That was the finding of a study reported here at the 19th European Congress on Obesity (ECO) by Anne Grunseit, PhD, from the Prevention Research Collaboration in the School of Public Health at the University of Sydney, Australia, and Norwegian colleagues. Research is increasingly focusing on sedentary behavior with low energy expenditure, including sitting and lying down, as behavioral risk factors for obesity and chronic disease. Sitting occurs during travel, while watching television, using computers, and reading. But with people often spending at least 9 hours a day at work, with fewer than 20% of jobs requiring physical exertion, and with many people spending at least 4 hours a day sitting at work, the sedentary time at work is high, and many people ar...